Polymorphisms in COMT and SULT1A1 Genes and Chronic Lymphocytic Leukemia Risk in Estonia
Objectives: Studies investigating associations between common polymorphisms in phase II metabolic enzymes COMT and SULT1A1 and the risk of various cancer types have revealed inconsistent and controversial results, with no attention turned to date to the most common adult leukemia type, i.e., chronic lymphocytic leukemia. Methods: In this small case-control study with 47 cases and 50 controls, the role of two functional polymorphisms, Val158Met in COMT gene and Arg213His in SULT1A1 gene affecting the activity level of respective enzymes, was studied on the susceptibility to chronic lymphocytic leukemia in an Estonian cohort. Results: Although statistically non-significant (p>0.05), the suggestive reduction in disease risk observed with low activity enzyme variants could indicate the involvement of O-methylation and sulfation of various endogenous and exogenous substances in the process of leukemogenesis. The odds ratio (OR) for Met158Met genotype of COMT was 0.60 with 95% confidence interval (95% CI) 0.20-1.82 compared to the wild type Val158Val genotype and the OR for His213His genotype of SULT1A1 was 0.58 with 95% CI 0.20-1.71 compared to the wild type Arg213Arg genotype. Conclusion: Further large-scale studies are highly needed to confirm or disprove the findings of the present study and determine genetic risk factors for chronic lymphocytic leukemia.
1.Voorhies BN, Stephens DM. What is optimal front-line therapy for chronic lymphocytic leukemia in 2017? Curr Treat Options Oncol 2017;18:12. [CrossRef]
2. Janroziak K, Pula B, Walewski J. Current treatment of chronic lymphocytic leukemia. Curr Treat Options Oncol 2017;18:5.
3. Robak T, Jamroziak K, Robak P. Current and emerging treatments for chronic lymphocytic leukaemia. Drugs 2009;69:2415–49. [CrossRef]
4. Parker H, Strefford JC. The mutational signature of chronic lymphocytic leukemia. Biochem J 2016;473:3725–40. [CrossRef]
5. Sak K, Everaus H. Sulfotransferase 1A1 as a biomarker for susceptibility to carcinogenesis: from molecular genetics to the role of dietary flavonoids. Curr Drug Metab 2016;17:528–41.
6. Sak K. The Val158Met polymorphism in COMT gene and cancer risk: role of endogenous and exogenous catechols. Drug Metab Rev 2017;49:56–83. [CrossRef]
7. Axelrod J, Senoh S, Witkop B. O-Methylation of catechol amines in vivo. J Biol Chem 1958;233:697–701.
8. Tian C, Liu L, Yang X, et al. The Val158Met polymorphism in the COMT gene is associated with increased cancer risks in Chinese population. Tumour Biol 2014;35:3003–8. [CrossRef]
9. Zhang H, Zhang Z, Wu J, et al. Lack of association between COMT Val158Met polymorphism and prostate cancer susceptibility. Urol Int 2013;91:213–9. [CrossRef]
10. Zou LW, Xu XJ, Liu T, et al. No association between COMT Val158Met polymorphism and prostate cancer risk: a metaanalysis. Genet Test Mol Biomarkers 2013;17:78–84. [CrossRef]
11. Zhou Q, Wang Y, Chen A, et al. Association between the COMT Val158Met polymorphism and risk of cancer: evidence from 99 case-control studies. Onco Targets Ther 2015;8:2791–803.
12. Matos A, Castelao C, Pereira da Silva A, et al. Epistatic interaction of CYP1A1 and COMT polymorphisms in cervical cancer. Oxid Med Cell Longev 2016;2769804. [CrossRef]
13. Naushad SM, Pavani A, Rupasree Y, et al. Modulatory effect of plasma folate and polymorphisms in one-carbone metabolism on catecholamine methyltransferase (COMT) H108L associated oxidative DNA damage and breast cancer risk. Indian J Biochem Biophys 2011;48:283–9.
14. Moreno-Galvan M, Herrera-Gonzalez NE, Robles-Perez V, et al. Impact of CYP1A1 and COMT genotypes on breast cancer risk in Mexican women: a pilot study. Int J Biol Markers 2010;25:157–63. [CrossRef]
15. Yager JD. Catechol-O-methyltransferase: characteristics, polymorphisms and role in breast cancer. Drug Discov Today Dis Mech 2012;9:e41–6. [CrossRef]
16. Doyle AE, Yager JD. Catechol-O-methyltransferase: effects of the val108met polymorphism on protein turnover in human cells. Biochim Biophys Acta 2008;1780:27–33. [CrossRef]
17. Lin G, Zhao J, Wu J, et al. Contribution of catechol-O-methyltransferase Val158Met polymorphism to endometrial cancer risk in postmenopausal women: a meta-analysis. Genet Mol Res 2013;12:6442–53. [CrossRef]
18. Lotta T, Vidgren J, Tilgmann C, et al. Kinetics of human soluble and membrane-bound catechol O-methyltransferase: a revised mechanism and description of the thermolabile variant of the enzyme. Biochemistry 1995;34:4202–10. [CrossRef]
19. Pan W, Liao H. Correlations between the COMT gene rs4680 polymorphism and susceptibility to ovarian cancer. Genet Mol Res 2015;14:16813–8. [CrossRef]
20. Ghisari M, Eiberg H, Long M, et al. Polymorphisms in phase I and phase II genes and breast cancer risk and relations to persistent organic pollutant exposure: a case-control study in Inuit women. Environ Health 2014;13:19. [CrossRef]
21. Li K, Li W, Zou H. Catechol-O-methyltransferase Val158Met polymorphism and breast cancer risk in Asian population. Tumour Biol 2014;35:2343–50. [CrossRef]
22. Du JZ, Dong YL, Wan GX, et al. Lack of association between the COMT rs4680 polymorphism and ovarian cancer risk: evidence from a meta-analysis of 3940 individuals. Asian Pac J Cancer Prev 2014;15:7941–5. [CrossRef]
23. Peng S, Tong X, Liu S, et al. Association between the COMT 158 G/A polymorphism and lung cancer risk: a meta-analysis. Int J Clin Exp Med 2015;8:17739–47.
24. Liu JX, Luo RC, Li R, et al. Lack of associations of the COMT Val158Met polymorphism with risk of endometrial and ovarian cancer: a pooled analysis of case-control studies. Asian Pac J Cancer Prev 2014;15:6181–6. [CrossRef]
25. Wolpert BJ, Amr S, Saleh DA, et al. Associations differ by sex for catechol-O-methyltransferase genotypes and bladder cancer risk in South Egypt. Urol Oncol 2012;30:841–7. [CrossRef]
26. Daniels J, Kadlubar S. Sulfotransferase genetic variation: from cancer risk to treatment response. Drug Metab Rev 2013;45:415–22. [CrossRef]
27. Tsukino H, Kuroda Y, Nakao H, et al. Cytochrome P450 (CYP) 1A2, sulfotransferase (SULT) 1A1, and N-acetyltransferase (NAT) 2 polymorphisms and susceptibility to urothelial cancer. J Cancer Res Clin Oncol 2004;130:99–106. [CrossRef]
28. Lindsay J, Wang LL, Li Y, Zhou SF. Structure, function and polymorphism of human cytosolic sulfotransferases. Curr Drug Metab 2008;9:99–105. [CrossRef]
29. Xiao J, Zheng Y, Zhou Y, et al. Sulfotransferase SULT1A1 Arg213His polymorphism with cancer risk: a meta-analysis of 53 case-control studies. PLoS One 2014;9:e106774. [CrossRef]
30. Arslan S, Silig Y, Pinarbasi H. Sulfotransferase 1A1 Arg(213) His polymorphism and prostate cancer risk. Exp Ther Med 2011;2:1159–62. [CrossRef]
31. Liu K, Ye J, Huang Y, et al. Quantitative analysis of the association between sulfotransferase isoform 1A1 polymorphism and risk of urothelial carcinoma. Mol Clin Oncol 2015;3:93– 100. [CrossRef]
32. Wang Z, Fu Y, Tang C, et al. SULT1A1 R213H polymorphism and breast cancer risk: a meta-analysis based on 8454 cases and 11800 controls. Breast Cancer Res Treat 2010;122:193–8. [CrossRef]
33. Yang G, Gao YT, Cai QY, et al. Modifying effects of sulfotransferase 1A1 gene polymorphism on the association of breast cancer risk with body mass index or endogenous steroid hormones. Breast Cancer Res Treat 2005;94:63–70. [CrossRef]
34. Wang Y, Spitz MR, Tsou AM, et al. Sulfotransferase (SULT) 1A1 polymorphism as a predisposition factor for lung cancer: a case-control analysis. Lung Cancer 2002;35:137–42. [CrossRef]
35. Baclig MO, Predicala RZ, Mapua CA, et al. Allelic and genotype frequencies of catechol-O-methyltransferase (Val158Met) and CYP2D6*10 (Pro34Ser) single nucleotide polymorphisms in the Philippines. Int J Mol Epidemiol Genet 2012;3:115–21.
36. Lajin B, Hamzeh AR, Ghabreau L, et al. Catechol-O-methyltransferase Val 108/158 Met polymorphism and breast cancer risk: a case control study in Syria. Breast Cancer 2013;20:62–6.
37. Tan X, Chen M. Association between catechol-O-methyltransferase rs4680 (G>A) polymorphism and lung cancer risk. Diagn Pathol 2014;9:192. [CrossRef]
38. Lavigne JA, Helslsouer KJ, Huang HY, et al. An association be-tween the allele coding for a low activity variant of catecholO-methyltransferase and the risk for breast cancer. Cancer Res 1997;57:5493–7.
39. Delort L, Chalabi N, Satih S, et al. Association between genetic polymorphisms and ovarian cancer risk. Anticancer Res 2008;28:3079–81.
40. Doherty JA, Weiss NS, Freeman RJ, et al. Genetic factors in catechol estrogen metabolism in relation to the risk of endometrial cancer. Cancer Epidemiol Biomarkers Prev 2005;14:357– 66. [CrossRef]
41. Onay UV, Aaltonen K, Briollais L, et al. Combined effect of CCND1 and COMT polymorphisms and increased breast cancer risk. BMC Cancer 2008;8:6. [CrossRef]
42. Su CM, Chen MC, Lin IC, et al. Association between the SULT1A1 Arg213His polymorphism and the risk of bladder cancer: a meta-analysis. Tumour Biol 2014;35:7147–53. [CrossRef]
43. Chung YT, Hsieh LL, Chen IH, et al. Sulfotransferase 1A1 haplotypes associated with oral squamous cell carcinoma susceptibility in male Taiwanese. Carcinogenesis 2009;30:286–94.
44. Koike H, Nakazato H, Ohtake N, et al. Further evidence for null association of phenol sulfotransferase SULT1A1 polymorphism with prostate cancer risk: a case-control study of familial prostate cancer in a Japanese population. Int Urol Nephrol 2008;40:947–51. [CrossRef]
45. Liang G, Miao X, Zhou Y, et al. A functional polymorphism in the SULT1A1 gene (G638A) is associated with risk of lung cancer in relation to tobacco smoking. Carcinogenesis 2004;25:773–8. [CrossRef]
46. Tang D, Rundle A, Mooney L, et al. Sulfotransferase 1A1 (SULT1A1) polymorphism, PAH-DNA adduct levels in breast tissue and breast cancer risk in a case-control study. Breast Cancer Res Treat 2003;78:217–22. [CrossRef]
47. Tiemersma EW, Voskuil DW, Bunschoten A, et al. Risk of colorectal adenomas in relation to meat consumption, meat preparation, and genetic susceptibility in a Dutch population. Cancer Causes Control 2004;15:225–36. [CrossRef]
48. Kellen E, Zeegers M, Paulussen A, et al. Does occupational exposure to PAHs, diesel and aromatic amines interact with smoking and metabolic genetic polymorphisms to increase the risk on bladder cancer?; The Belgian case control study on bladder cancer risk. Cancer Lett 2007;245:51–60. [CrossRef]
49. Nowell S, Coles B, Sinha R, et al. Analysis of total meat intake and exposure to individual heterocyclic amines in a case-control study of colorectal cancer: contribution of metabolic variation to risk. Mutat Res 2002;506–7:175–85. [CrossRef]
50. Ashton KA, Meldrum CJ, McPhillips ML, et al. The association of the COMT V158M polymorphism with endometrial/ovarian cancer in HNPSS families adhering to the Amsterdam criteria. Hered Cancer Clin Pract 2006;4:94–102. [CrossRef]
51. Zienolddiny S, Campa D, Lind H, et al. A comprehensive analysis of phase I and phase II metabolism gene polymorphisms and risk of non-small cell lung cancer in smokers. Carcinogenesis 2008;29:1164–9. [CrossRef]
52. Zheng W, Xie D, Cerhan JR, et al. Sulfotransferase 1A1 polymorphism, endogenous estrogen exposure, well-done meat intake, and breast cancer risk. Cancer Epidemiol Biomarkers Prev 2001;10:89–94.
53. Roubalova L, Purchartova K, Papouskova B, et al. Sulfation modulates the cell uptake, antiradical activity and biological effects of flavonoids in vitro: an examination of quercetin, isoquercitrin and taxifolin. Bioorg Med Chem 2015;23:5402–9.
54. Rebbeck TR, Troxel AB, Wang Y, et al. Estrogen sulfation genes, hormone replacement therapy, and endometrial cancer risk. J Natl Cancer Inst 2006;98:1311–20. [CrossRef]
55. Lilla C, Risch A, Kropp S, Chang-Claude J. SULT1A1 genotype, active and passive smoking, and breast cancer risk by age 50 years in a German case-control study. Breast Cancer Res 2005;7:R229–37. [CrossRef]
56. Sak K, Everaus H. Nanotechnological approach to improve the bioavailability of dietary flavonoids with chemopreventive and anticancer properties. In: Grumezescu A, ed. Nutraceuticals, vol. 4. Academic Press, 2016:427–79. [CrossRef]
57. Chen Z, Chen M, Pan H, et al. Role of catechol-O-methyltransferase in the disposition of luteolin in rats. Drug Metab Dispos 2011;39:667–74. [CrossRef]
58. Chen Z, Zheng S, Li L, Jiang H. Metabolism of flavonoids in human: a comprehensive review. Curr Drug Metab 2014;15:48– 61. [CrossRef]
59. Zhu BT, Patel UK, Cai MX, et al. Rapid conversion of tea catechins to monomethylated products by rat liver cytosolic catechol-Omethyltransferase. Xenobiotica 2001;31:879–90. [CrossRef]
60. Zhu BT. Catechol-O-methyltransferase (COMT)-mediated methylation metabolism of endogenous bioactive catechols and modulation by endobiotics and xenobiotics: importance in pathophysiology and pathogenesis. Curr Drug Metab 2002;3:321–49. [CrossRef]
61. Jiang W, Hu M. Mutual interactions between flavonoids and enzymatic and transporter elements responsible for flavonoid disposition via phase II metabolic pathways. RSC Adv 2012;2:7948–63. [CrossRef]
62. Nakano H, Ogura K, Takahashi E, et al. Regioselective monosulfation and disulfation of the phytoestrogens daidzein and genistein by human liver sulfotransferases. Drug Metab Pharmacokinet 2004;19:216–26. [CrossRef]
63. Sak K. Cytotoxicity of dietary flavonoids on different human cancer types. Pharmacogn Rev 2014;8:122–46. [CrossRef]
64. Sak K. Site-specific anticancer effects of dietary flavonoid quercetin. Nutr Cancer 2014;66:177–93. [CrossRef]
65. Landis-Piwowar K, Chen D, Chan TH, Dou QP. Inhibition of catechol-omicron-methyltransferase activity in human breast cancer cells enhances the biological effect of the green tea polyphenol (-)-EGCG. Oncol Rep 2010;24:563–9. [CrossRef]
66. Wang P, Aronson WJ, Huang M, et al. Green tea polyphenols and metabolites in prostatectomy tissue: implications for cancer prevention. Cancer Prev Res (Phila) 2010;3:985–93. [CrossRef]
67. Forester SC, Lambert JD. Synergistic inhibition of lung cancer cell lines by (-)-epigallocatechin-3-gallate in combination with clinically used nitrocatechol inhibitors of catechol-Omethyltransferase. Carcinogenesis 2014;35:365–72. [CrossRef]
68. Lorenz M, Paul F, Moobed M, et al. The activity of catecholO-methyltransferase (COMT) is not impaired by high doses of epigallocatechin-3-gallate (EGCG) in vivo. Eur J Pharmacol 2014;740:645–51. [CrossRef]
69. Landis-Piwowar KR, Wan SB, Wiegand RA, et al. Methylation suppresses the proteasome-inhibitory function of green tea polyphenols. J Cell Physiol 2007;213:252–60. [CrossRef]
70. Nicolini F, Burmistrova O, Marrero MT, et al. Induction of G2/M phase arrest and apoptosis by the flavonoid tamarixetin on human leukemia cells. Mol Carcinog 2014;53:939–50. [CrossRef]
71. Shi ZH, Li NG, Tang YP, et al. Biological evaluation and SAR analysis of O-methylated analogs of quercetin as inhibitors of cancer cell proliferation. Drug Dev Res 2014;75:455–62. [CrossRef]
72. Delgado L, Fernandes I, Gonzalez-Manzano S, et al. Anti-proliferative effects of quercetin and catechin metabolites. Food Funct 2014;5:797–803. [CrossRef]
73. Androutsopoulos VP, Spandidos DA. The flavonoids diosmetin and luteolin exert synergistic cytostatic effects in human hepatoma HepG2 cells via CYP1A-catalyzed metabolism, activation of JNP and ERK and P53/P21 up-regulation. J Nutr Biochem 2013;24:496–504. [CrossRef]
74. Barrajon-Catalan E, Taamalli A, Quirantes-Pine R, et al. Differential metabolomic analysis of the potential antiproliferative mechanism of olive leaf extract on the JIMT-1 breast cancer cell line. J Pharm Biomed Anal 2015;105:156–62. [CrossRef]
75. Vaidyanathan JB, Walle T. Glucuronidation and sulfation of the tea flavonoid (-)-epicatechin by the human and rat enzymes. Drug Metab Dispos 2002;30:897–903. [CrossRef]
76. Yang CH, Tang L, Lv C, et al. Sulfation of selected mono-hydroxyflavones by sulfotransferases in vitro: a species and gender comparison. J Pharm Pharmacol 2011;63:967–70. [CrossRef]
77. Skibola CF, Bracci PM, Paynter RA, et al. Polymorphisms and haplotypes in the cytochrome P450 17A1, prolactin, and catechol-O-methyltransferase genes and non-Hodgkin lymphoma risk. Cancer Epidemiol Biomarkers Prev 2005;14:2391– 401. [CrossRef]
78. Sak K, Kasemaa K, Everaus H. Change of COMT Val158Met genotype in tumoral B cells of a chronic lymphocytic leukemia patient: a case report. Ann Hematol Oncol 2017;4:1130. [CrossRef]